NICE nod for Lynparza in prostate cancer group without biomarker test

21 December 2023
lynparza_big

Lynparza (olaparib) has been recommended for use alongside abiraterone and prednisone or prednisolone for untreated hormone-relapsed metastatic prostate cancer in UK adults who cannot or will not have chemotherapy, regardless of biomarker status.

The AstraZeneca (LSE: AZN) and Merck & Co (NYSE: MRK) drug has been recommended in this group in a Final Draft Guidance from the UK cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE).

"This is the first time that patients with this form of prostate cancer will be able to access a PARP inhibitor without the need for a specific biomarker test"Noel Clarke, professor of Urological Oncology at The Christie, and Salford Royal Hospitals, said: “Data from the PROpel Phase III trial show that olaparib in combination with abiraterone and prednisone or prednisolone provides real benefit for men with metastatic castration-resistant prostate cancer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology